H. Lundbeck A/S today announced positive headline results from a
newly unblinded proof of concept clinical study with the compound Lu
AA21004 for the treatment of Major Depressive Disorder.
The clinical trial was a multicenter, double-blind,
placebo-controlled trial including 426 patients with major
depression. Lu AA21004 showed highly significant improvements on the
primary efficacy endpoints with both 5 and 10 mg compared to placebo
and had an attractive safety profile."We are pleased that the encouraging results from this proof of
concept study confirm our experimental expectations of Lu AA21004 as
a potent and well tolerated new drug for the treatment of major
depression," says Anders Gersel Pedersen, Head of Development at
Lundbeck and continues: "Lu AA21004 is the most advanced project
within the new bis-aryl-sulphanyl amine class of compounds for the
treatment of mood disorders and anxiety, and we look forward to
further exploiting the potential of these novel projects."
Lu AA21004 is jointly being developed by H. Lundbeck A/S and Takeda
Pharmaceutical Company Limited. Following analysis of the phase II
data, Lundbeck and Takeda will plan the next steps in the development
of Lu AA21004.
The content of this release will have no influence on the Lundbeck
Group's financial result for 2007.
Lundbeck contacts
Investors: Media:
Jacob Tolstrup Caroline Broge
Director, Investor Relations Media Relations Manager
+45 36 43 30 79 +45 36 43 26 38
+1 201 350 0187
________________________
Stock Exchange Release No 296 - 2 October 2007
About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of drugs
for the treatment of psychiatric and neurological disorders. In 2006,
the company's revenue was DKK 9.2 billion (approximately EUR 1.2
billion or USD 1.6 billion). The number of employees is approximately
5,300 globally. For further information, please visit
www.lundbeck.com
